

## AMPOXIN-CV FORTE

**To be sold by retail on prescription of R.M.P. only**

Abbreviated Prescribing information for **AMPOXIN-CV FORTE** (Amoxicillin & Potassium Clavulanate Oral Suspension I.P.) [Please refer the complete prescribing information available at [www.torrentpharma.com](http://www.torrentpharma.com)]

**PHARMACOLOGICAL PROPERTIES:** Amoxicillin is a semisynthetic penicillin (beta-lactam antibiotic) that inhibits one or more enzymes (often referred to as penicillin-binding proteins, PBPs) in the biosynthetic pathway of bacterial peptidoglycan, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to weakening of the cell wall, which is usually followed by cell lysis and death. Clavulanic acid is a beta-lactam structurally related to penicillins. It inactivates some beta-lactamase enzymes thereby preventing inactivation of amoxicillin. Clavulanic acid alone does not exert a clinically useful antibacterial effect.

**INDICATIONS:** It is indicated for the treatment of LRTI infections (e.g. Pneumonia, bronchitis), acute otitis media, sinusitis, UTI, skin & soft tissue infections & bone & joint infections.

**DOSAGE AND ADMINISTRATION:** As directed by the Physician.

**CONTRAINDICATION:** Hypersensitivity to the active substances, to any of the penicillins or to any excipients. History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to another beta-lactam agent (e.g. a cephalosporin, carbapenem or monobactam). History of jaundice/hepatic impairment due to amoxicillin/clavulanic acid.

**WARNINGS & PRECAUTION:** Enquire previous hypersensitivity reactions to penicillins, cephalosporins or other beta-lactam agents. Convulsions may occur in patients with impaired renal function or in those receiving high doses. Concomitant use of allopurinol an increase allergic skin reactions. Acute generalised exanthemous pustulosis (AGEP) may occur.

**DRUG INTERACTIONS:** If patient is taking oral anticoagulants (acenocoumarol or warfarin) prothrombin time or international normalised ratio should be carefully monitored. Interactions may also occur with methotrexate, probenecid and mycophenolate mofetil.

**ADVERSE REACTIONS:** Mucocutaneous candidosis, overgrowth of non-susceptible organisms, reversible leucopenia (including neutropenia), thrombocytopenia, reversible agranulocytosis, haemolytic anaemia, prolongation of bleeding time and prothrombin time, angioneurotic oedema, anaphylaxis, serum sickness-like syndrome, hypersensitivity vasculitis, dizziness, headache, reversible hyperactivity, diarrhoea, vomiting, indigestion, rises in AST and/or ALT, hepatitis, cholestatic jaundice, skin rash, pruritus, urticaria, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous exfoliative-dermatitis, acute generalised exanthemous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), interstitial nephritis, crystalluria.

**MARKETED BY:**



MARKETED BY TORRENT PHARMACEUTICALS LTD.

**IN/ AMPOXIN CV FORTE 400 and 57 mg/APR-20/01/AbPI**

(Additional information is available on request)